MannKind Corporation filings document formal disclosures for a Nasdaq-listed biopharmaceutical company focused on inhaled and drug-device therapies. Its 8-K reports furnish operating results and business updates for Afrezza, Furoscix and pipeline programs, while also recording capital-structure events such as convertible-note settlement and material collaboration agreements involving the Technosphere platform.
The filing record also includes acquisition-related disclosures for the completed scPharma transaction, including acquired-business financial statements and pro forma combined financial information. MannKind proxy materials address annual meeting matters, executive compensation and equity-award information, and other governance subjects tied to its common stock.
MNKD amendment (Form 144/A) reports a proposed sale of Common securities related to Restricted Stock Units with transaction dates listed as 05/10/2026 and 05/12/2026. The filing lists Morgan Stanley Smith Barney LLC as the broker. The filing amends prior information and records broker and security details for a resale filing.
MANNKIND CORP Chief People & Workplace Officer Stuart A. Tross reported a routine tax-related share disposition. On the vesting of restricted stock units originally granted on May 10, 2022, 8,073 shares of common stock were withheld to cover tax withholding obligations at a value of $3.52 per share. After this non-market transaction, Tross directly holds 992,224 shares of MANNKIND CORP common stock.
MannKind Corp director Steven B. Binder reported an open-market sale of 16,940 shares of common stock at a weighted average price of $3.29 per share on May 12, 2026, executed under a Rule 10B5-1 trading plan established on December 2, 2025.
Binder also had 5,560 shares withheld on May 11, 2026 to cover tax obligations arising from the vesting of restricted stock units originally granted on May 10, 2022. Following these transactions, he directly holds 808,008 MannKind shares.
MANNKIND CORP Chief Executive Officer Michael Castagna reported a routine share withholding related to taxes on vested equity. On May 11, 34,957 shares of common stock were withheld at $3.52 per share to satisfy tax withholding obligations from Restricted Stock Units originally granted on May 10, 2022.
These shares were not sold in the open market but used to cover taxes due at vesting. After this transaction, Castagna directly holds 2,442,310 shares of MannKind common stock, which includes 1,356 shares acquired under the company’s Employee Stock Purchase Plan on December 31, 2025.
MannKind Corp executive David Thomson, EVP, General Counsel & Secretary, reported recent transactions in the company’s common stock. He completed an open-market sale of 3,033 shares at a weighted average price of $3.29 per share, executed pursuant to a pre-arranged Rule 10b5-1 trading plan established on August 27, 2025. Separately, 12,387 shares were withheld to cover tax obligations tied to the vesting of restricted stock units that were originally granted on May 10, 2022, which is a non-market, tax-related disposition. After these transactions, Thomson directly holds 826,299 shares of MannKind common stock.
MannKind Corp ownership disclosure: State Street Corporation reports beneficial ownership of 18,683,483 shares of Common Stock, representing 6.1% of the class. The filing lists shared voting power of 17,967,218 and shared dispositive power of 18,683,483, with certain holdings attributed to State Street affiliates.
MANNKIND CORP Chief Executive Officer Michael Castagna filed an amended insider report clarifying that a previously filed Form 4 was erroneous. The earlier Form 4 had mistakenly shown him directly acquiring 100,000 MannKind common shares on March 10, 2026.
The amendment explains these shares were actually acquired by his spouse in a segregated retirement account in which he has no pecuniary interest, so the transaction should not be attributed to him and the prior Form 4 should be deemed revoked. As of March 10, 2026, he is reported as directly owning 2,475,911 MannKind common shares.
MannKind Corporation reported a net loss for the quarter ended March 31, 2026 despite higher revenue. Total revenues rose to $90.2 million from $78.4 million, driven by commercial product sales of $33.9 million, collaborations and services of $23.5 million, and royalties of $32.7 million.
Total expenses increased to $91.8 million, including higher research and development and selling, general and administrative costs, leading to a loss from operations of $1.7 million. After $14.7 million in net other expense, MannKind recorded a net loss of $16.6 million, or $0.05 per basic and diluted share. Cash, cash equivalents and restricted cash were $53.6 million, with total assets of $744.4 million and total liabilities of $803.6 million, resulting in stockholders’ deficit of $59.2 million.
MannKind Corporation reported a net loss for the quarter ended March 31, 2026 despite higher revenue. Total revenues rose to $90.2 million from $78.4 million, driven by commercial product sales of $33.9 million, collaborations and services of $23.5 million, and royalties of $32.7 million.
Total expenses increased to $91.8 million, including higher research and development and selling, general and administrative costs, leading to a loss from operations of $1.7 million. After $14.7 million in net other expense, MannKind recorded a net loss of $16.6 million, or $0.05 per basic and diluted share. Cash, cash equivalents and restricted cash were $53.6 million, with total assets of $744.4 million and total liabilities of $803.6 million, resulting in stockholders’ deficit of $59.2 million.